Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
4.
The American Journal of Emergency Medicine ; 43:259, 2021.
Article in English | ProQuest Central | ID: covidwho-1209609
8.
Brain Behav Immun Health ; 13: 100217, 2021 May.
Article in English | MEDLINE | ID: covidwho-1077784

ABSTRACT

OBJECTIVE: To report a patient with history of recurrent Bell's Palsy who developed Bell's Palsy 36 â€‹h after the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine. CASE: The patient is a 57-year-old female with past medical history of 3 episodes of Bell's Palsy. She responded to prednisone treatment and returned to her baseline after each occurrence. Less than 36 â€‹h following the second dose of the vaccine, the patient developed a left Bell's Palsy. The facial droop progressed in severity over the next 72 â€‹h. CONCLUSION: Given the expedited production of the vaccine and the novelty associated with its production, there may be information pertaining to side effects and individual response that remain to be discovered. Since both the Moderna and Pfizer Vaccine trials reported Bell's Palsy as medically attended adverse events, the association between vaccine administration and onset of symptomatic Bell's Palsy may warrant further investigation.

9.
Acta Biomed ; 91(4): e2020199, 2020 11 27.
Article in English | MEDLINE | ID: covidwho-1058722

ABSTRACT

BACKGROUND AND AIM: Letter to Editor, report the amount of literature generated over two weeks on PubMed.gov related to COVID-19 Methods: reporting the daily number of "hits" from "COVID-19" search on PubMed.gov Results: There were 66988 entries on PubMed.gov on the search word "COVID-19" on October 24, 2020. The average daily increase in number of entries was 335. CONCLUSIONS: point out the fact that the literature volume is increasing in an exponential manner (www.actabiomedica.it).


Subject(s)
COVID-19 , Humans , PubMed , Publishing , Research Report , SARS-CoV-2
10.
Brain Behav Immun Health ; 12: 100203, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1025497

ABSTRACT

BACKGROUND: Guillain Barre Syndrome (GBS) and Miller Fisher Syndrome (MFS) are emerging as known consequences of COVID-19 infection. However, there have been no reported cases with positive GM1 or GQ1b antibodies in the literature to date. Although clinically similar, the pathophysiology of COVID-19 related GBS and MFS may be significantly different from cases in the pre-pandemic era. CASE PRESENTATION: We present a patient with ascending areflexic weakness consistent with GBS with positive GM1 antibody. The patient had recovered from COVID-19 infection two weeks prior with mild viral illness and symptoms. Her weakness was isolated to the lower extremities and improved after intravenous immunoglobulin treatment. Patient recovered eventually. CONCLUSIONS: - The general lack of reported ganglioside antibodies supports a novel target(s) for molecular mimicry as the underlying etiology, which raises the concern for possible vaccine induced complication. Whether the current GM1 positive case is a sequalae of COVID-19 or a mere coincidence is inconclusive. Further understanding of the disease mechanism of pandemic era GBS and MFS, including antigen target(s) of COVID-19, may be of utmost importance to the development of a safe COVID-19 vaccine.

11.
Cureus ; 13(1): e12424, 2021 Jan 01.
Article in English | MEDLINE | ID: covidwho-1013551

ABSTRACT

Although Miller Fisher syndrome cases have been published in this coronavirus disease 2019 (COVID-19) pandemic, anti-GQ1b antibody has not been identified so far. A direct proof of association is not yet available since the exact pathophysiology is not known. Using a proof of contradiction argument, lack of GQ1b serves as the indirect proof that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is probably the infection preceding demyelination. A novel antigen has yet to be described.

12.
Cureus ; 12(10): e11186, 2020 Oct 26.
Article in English | MEDLINE | ID: covidwho-902954

ABSTRACT

It is well-established by now that COVID-19 can have a wide variety of neuromuscular manifestations, including rhabdomyolysis. Weakness and elevated creatinine kinase (CK) have been documented as the initial presentation of COVID-19. Myopathy from statin use has also been well-established since the introduction of this class of medication, and the common pathologic mechanism of both entities may have been mitochondrial dysfunction. We present here the case of a COVID-19 patient on rosuvastatin who developed rhabdomyolysis with CK above 1,000,000 units/L. The patient did not present with any respiratory difficulty and responded poorly to treatment, resulting in his untimely demise. COVID-19 may have accentuated an otherwise survivable condition by means of extra stress on mitochondrial homeostasis. Understanding the actual mechanism will be important in the development and utilization of medications in the fight against COVID-19.

13.
Rambam Maimonides Med J ; 12(1)2021 Jan 19.
Article in English | MEDLINE | ID: covidwho-895577
14.
SELECTION OF CITATIONS
SEARCH DETAIL